Orencia 125 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FX3SF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $70,486
Award facts
- Contract value 100% obligated
- $70,485.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $70,485.61 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract has an ultimate completion date of October 23, 2025, and carries no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is a child contract issued under AmerisourceBergen's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026 that enables the contractor to supply pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across the Department of Defense and Veterans Affairs healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This order for Orencia—a biologic immunosuppressant used in rheumatoid arthritis treatment—reflects the contractor's role in supplying essential pharmaceutical therapies to military and federal healthcare beneficiaries. The DLA has indicated plans to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen among the anticipated qualified contractors for continued pharmaceutical supply support.
Quick answers
Who was awarded contract SPE2DB26FX3SF?
SPE2DB26FX3SF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DB26FX3SF worth?
The government has obligated $70,486 on SPE2DB26FX3SF.
Is contract SPE2DB26FX3SF an order under another contract?
Yes. SPE2DB26FX3SF is a delivery order under SPE2DB22D3301, an indefinite delivery contract.
Was contract SPE2DB26FX3SF competed?
The extent of competition for SPE2DB26FX3SF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award